Mink Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Mink Therapeutics

01/11/2023 12:09

* Mink Therapeutics Inc  INKT.OQ   INKT.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Mink Therapeutics
Inc is
for a loss of 18 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mink
Therapeutics
Inc is $8​, above​ its last closing price of $1.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.19       -0.20      -0.18     Beat    8.9
 Mar. 31 2023  -0.25       -0.24      -0.17     Beat    28.4
 Dec. 31 2022              -0.21      -0.23     Missed  -9.5​
 Sep. 30 2022  -0.23       -0.23      -0.19     Beat    18.3
 ​​Jun.        -0.24       -0.24      -0.18     Beat    25
 30 2022                                                
 Mar. 31 2022  -0.21       -0.21      -0.23     Missed  -11.3​
 Dec. 31 2021  -0.41       -0.41      -0.18     Beat    56.1
 Sep. 30 2021  -0.20       -0.20      -0.59     Missed  -187.8
 This summary was machine generated November 1 at 12:09 GMT.  All
figures in US dollars  unless otherwise stated